ArticleJACC. Case reports2025
Sustained Monomorphic Ventricular Tachycardia Accurately Detected by Wearable Technology.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wearable devices are increasingly used to detect arrhythmias, including life-threatening ventricular tachycardia (VT). This case highlights their role in clinical settings. A patient with prior surgical aortic valve replacement because of a bicuspid valve experienced symptomatic palpitations, and his smartwatch recorded a wide complex tachycardia at 165 beats/min. His presentation led to intensive care admission and later to a diagnosis of VT successfully treated with an implantable defibrillator and ultimately requiring radiofrequency ablation. Smartwatches provide a noninvasive tool for detecting arrhythmias like VT, using photoplethysmography and single-lead ECG. Limitations include validation gaps, false positives, and user activation. Integration into clinical practice requires updated guidelines, structured reimbursement, and legal clarity. This case demonstrates the critical role of smartwatch data in VT detection and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.